TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00106210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention blending several tx approaches, w/ focus
Description: Early intervention blending several different treatment approaches, with a focus on certain skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early intervention blending several treatment approaches
Description: Early intervention blending several different treatment approaches
Study: NCT02321202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid-Based Parenteral Nutrition
Description: Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Structolipid
Description: Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Study: NCT02295943

Intervention type: OTHER
Group type: OTHER
Intervention: Positioning measuring device
Description: Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
Study: NCT02999802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive resistance exercise training
Study: NCT02169362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Description: Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Description: Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
Study: NCT02823990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03134105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Feedback on activity and patient-reported angina
Description: Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-of-Study Feedback
Description: Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
Study: NCT04165031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study: NCT03293160

Intervention type: OTHER
Intervention: Care management services
Description: Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
Study: NCT00039390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01695031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored asthma management program
Description: web-based, computer-tailored asthma management intervention delivered every week for 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic web-based education
Description: Generic, web-based asthma education
Study: NCT01132443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Description: Apply topically once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Description: Apply topically once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Description: Apply topically once daily
Study: NCT00130260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staph aureus types 5 and 8 conjugate vaccine
Description: each IM dose contains 200 mc total conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staph aureus types 5 and 8 conjugate vaccine
Description: each IM dose contains 200 mc total conjugate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match StaphVAX

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match StaphVAX
Study: NCT01133795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine plus Albumin
Description: MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
Study: NCT00921687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The education will consist of a lecture and distribution of a CKD reference card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
Study: NCT03787459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol
Description: Oseltamivir plus Arbidol will be administrated from Days 1-7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Oseltamivir plus placebos will be administrated from Days 1-7.
Study: NCT02270541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: In-ambulance telemedicine
Study: NCT02767284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V1
Description: A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V2
Description: A refined version of the UCST-V1 that randomizes frequency order.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V3
Description: A version that utilises eye-tracking technology to make the measurements more accurate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick-CSF (QCSF)
Description: A fast contrast sensitivity measurement method using a Bayesian algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelli-Robson
Description: A standard method developed using a Sloan-letter chart with decreasing contrast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optec 6500
Description: A standard test using sinusoidal gratings to measure the contrast sensitivity function.
Study: NCT03479853

Intervention type: PROCEDURE
Intervention: Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)
Description: Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.

Intervention type: PROCEDURE
Intervention: Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)
Description: Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
Study: NCT04465253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care occupational therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participate in discussions via videoconferencing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participate in interview via videoconferencing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04393558

Intervention type: DEVICE
Intervention: ADAM Sensor
Description: ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.

Intervention type: DEVICE
Intervention: ADAM Sensor
Description: ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
Study: NCT03934138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational movie on placebo mechanisms
Description: Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Informative movie on hand washing
Description: Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
Study: NCT01470053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate plus azelastine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine HCl
Study: NCT02402673

Intervention type: OTHER
Group type: OTHER
Intervention: Temporary activity modification and graded exercises
Study: NCT01046864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
Study: NCT00860639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemtuzumab ozogamycin
Description: gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
Study: NCT01022203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Approach Therapy
Description: The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
Study: NCT02323451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Chitosan
Description: intra-articular injection
Study: NCT01022203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Family Education
Description: The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
Study: NCT04576013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive upper extremity motor training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive upper extremity motor training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive upper extremity motor training
Study: NCT03949881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FEMJA transplatation
Description: The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
Study: NCT03556995

Intervention type: OTHER
Intervention: bariatric surgery patients
Study: NCT01042340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calogen® - an energy dense oleic acid based formula
Description: A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
Study: NCT03874793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study: NCT04584814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Basal analysis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scare ventilator at 20
Description: To set scare ventilator by 20 cycles per minute
Study: NCT02323451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate Injection
Description: intra-articular injection
Study: NCT03866798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: Immune Globulin, intravenous, human-ifas
Study: NCT03829475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is an infusion of normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT is an infusion of prescreened donor stool that will be administered via colonoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
Study: NCT00836745

Intervention type: OTHER
Intervention: Non Interventional
Description: Sutent capsule, once daily administered per the locally approved product information.
Study: NCT04584814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scare ventilator at 40
Description: To set scare ventilator by 40 cycles per minute
Study: NCT01628562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol 50 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil 0.5 mcg/kg/min
Study: NCT02450045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture
Study: NCT03930862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator Attachment (positioner)
Description: intra oral attachment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator Attachment (positioner)
Description: intra oral attachment
Study: NCT01552603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control Software
Description: This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
Study: NCT02961803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo